BOARD OF DIRECTORS

Ann Childress, M.D.
President
Psychiatrist Center for Psychiatry and Behavioral Medicine, Inc.

Gregory Mattingly, M.D.
President-Elect
Washington University School of Medicine

Jeffrey Newcorn, M.D.
Past President
Mt. Sinai Medical Center

David Goodman, M.D.
Treasurer
Johns Hopkins School of Medicine

Margaret Sibley, Ph.D.
Secretary
University of Washington School of Medicine

BOARD MEMBERS

Maria Acosta, M.D.*
NHGRI/NIH
*Dr. Acosta is serving in a personal capacity

Mark Bertin, M.D.
New York Medical College

Sam Goldstein, Ph.D.
Postjournal of Attention Disorders

Frances Levin, M.D.
Columbia University

Joel Nigg, Ph.D.
Center for ADHD Research at Oregon Health & Science University

Erin Schoenfelder Gonzalez, Ph.D.
University of Washington

Mark Stein, Ph.D.
University of Washington

Anne Arnett, Ph.D.
Boston Children’s Hospital/Harvard Medical School

Thomas Brown, Ph.D.
Keck School of Medicine of University of Southern California

Martin Katzman, M.D., B.Sc., FRCP(C)
START Clinic for Mood and Anxiety Disorders

Keith McBurnett, Ph.D.
University of California, San Francisco

Keri Rosch, Ph.D.
Center for Neurodevelopmental and Imaging Research at Kennedy Krieger Institute

Julie Schweitzer, Ph.D.
MIND Institute, UC Davis School of Medicine

James Waxmonsky, M.D.
Penn State College of Medicine

Jacob Behrens, M.D.
Envision ADHD

J Faye Dixon, Ph.D.
UC Davis Medical Center

Beth Krone, Ph.D.
Clinical Research Coordinator-Post Doc

Brooke Molina, Ph.D.
Professor of Psychiatry, Psychology, and Pediatrics

Douglas Russell, M.D.
University of Washington / Seattle Children’s

Philip Shaw, Ph.D.
National Human Genome Research Institute*
*Dr. Shaw is serving in a personal capacity

Cathi Zillman, PMHNP, CPNP
South Shore Child Guidance Center
APSARD would not be successful without the hard work of our board members. We are grateful for their time, dedication and passion for better the field of ADHD and related disorders.

To our departing board members, thank you for your commitment to APSARD, we look forward to growing your legacy.

**DEPARTING BOARD MEMBERS**

Maria Acosta, M.D.*
NHGRI/NIH
*Dr. Acosta is serving in a personal capacity

Joel Nigg, Ph.D.
Center for ADHD Research at Oregon Health & Science University

Keith McBurnett, Ph.D.
University of California, San Francisco

Thomas Brown, Ph.D.
Keck School of Medicine of University of Southern California

**2023 PROGRAM COMMITTEE**

Co-Chair
Brooke Molina, Ph.D.
University of Pittsburgh

Co-Chair
Frances Levin, M.D.
Columbia University Medical Center

Ann Childress, M.D.
Psychiatrist Center for Psychiatry and Behavioral Medicine, Inc.

Margaret Sibley, Ph.D.
University of Washington School of Medicine

Joel Nigg, Ph.D.
Oregon Health & Science University

Jeffrey Newcorn, M.D.
Icahn School of Medicine at Mount Sinai

Margaret Weiss, MD, PhD, FRCP(C)
Cambridge Health Alliance

John Mitchell, Ph.D.
Duke University Medical Center

Gregory Mattingly, M.D.
Washington University School of Medicine

Steven Pliszka, M.D.
University of Texas San Antonio

Mariely Hernandez, Ph.D.
Columbia University Medical Center

Martin Katzman, M.D., B.Sc., FRCP(C)
START Clinic for Mood and Anxiety Disorders
Join us to hear viewpoints from multiple perspectives on adult ADHD treatment

SATURDAY, JANUARY 14TH
2:30-3:30 PM
Renaissance Orlando SeaWorld, Peninsula 4

Clinical Conundrum: Appropriate Use of Stimulant Medications in Adults With ADHD

Greg Mattingly, MD
St. Charles Psychiatric Associates
Washington University

Oren Mason, MD
Attention MD
Grand Rapids, MI
A NOVEL, NONSTIMULANT APPROACH IN ADULT ADHD

Less chaos... More control

ADHD does not need to get in the way of adulting

Supernus Pharmaceuticals proudly supports the 2023 APSARD Annual Conference.

INDICATION
Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS
• Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
• Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS
• Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; APSARD, The American Professional Society of ADHD and Related Disorders.


Please see the full Prescribing Information, including Boxed Warning at QelbreeHCP.com.
Don’t Let ADHD Fly Under the Radar
Recognition and Treatment of ADHD in the Context of Comorbidity

FRIDAY, JANUARY 13, 2023 | 1:00 PM – 2:00 PM ET

REGISTRATION AND MEAL: 12:30 PM | PRESENTATION: 1:00 PM

RENAISSANCE ORLANDO AT SEA WORLD, 6677 SEA HARBOR DRIVE
ORLANDO, FLORIDA | PENINSULA 4

MODERATOR
Ann Childress, MD
President
Center for Psychiatry
and Behavioral Medicine, Inc.
President, APSARD - American Professional Society for ADHD and Related Disorders
Las Vegas, Nevada

PANELISTS
Vladimir Maletic, MD, MS
Clinical Professor of Psychiatry
USC School of Medicine
Greenville, South Carolina

Gregory W. Mattingly, MD
Associate Clinical Professor
Washington University School of Medicine
President, Midwest Research Group
President Elect, APSARD - American Professional Society for ADHD and Related Disorders
St. Louis, Missouri

For more information and to register, visit:
www.medscape.org/townhall/adhd-radar

Supported by an independent educational grant from Supernus Pharmaceuticals, Inc.
Do your adult patients desire flexibility from their ADHD medication?

JOIN US FOR A BREAKFAST PRESENTATION:

A Tailored Treatment for Adults With ADHD

Speaker: Greg Mattingly, MD
Date: Saturday
Time: 8:00 AM - 9:00 AM

Dr. Gregory Mattingly, MD: Associate Clinical Professor, Washington University; President, Midwest Research Group; President Elect, American Professional Society for ADHD and Related Disorders (APSARD). Dr. Mattingly is a paid consultant of Noven Pharmaceuticals, Inc.

And visit us at our booths to learn more about Noven’s mission to improve patients’ lives with transdermal drug delivery systems.
Networking has never been so easy! Introducing the newest APSARD Member Benefit, Special Interest Groups (SIGs). Join the conversations today with like-minded APSARD professionals.

APSARD is thrilled to introduce Special Interest Groups (SIGs) as a new member benefit! Special Interest Groups help establish better relationships, enable networking, and information exchange. Through the leadership of our dedicated SIG Co-Chairs, members with shared interests will have the opportunity to meet and discuss ideas, trends, issues, and thoughts. We hope that all of our members will find at least one of our inaugural SIGs to participate in!

You can learn more about each SIG Group on our website HERE.

Our inaugural SIGs are:
- College Students & ADHD
- ADHD & Substance Use Disorders
- Pediatrics-Psychiatry Interface
- Women & Girls with ADHD
- Technology & ADHD

For additional information please email the Executive Office at info@apsard.org.
We are grateful for the generous support of our sponsors and exhibitors!